Skip to content
Signal Bureau What’s happening · what the record shows

Genentech

A topic on our watch list — we track its coverage across 2 domains, including Biotech Pharma and KRAS Research.

Coverage of Genentech is newly on the wire: 5 signals on the latest tracked day, level with its three-week baseline of 5, across 2 domains. That makes it the #333 most-covered of the 349 concerns we track.

If Genentech matters to your work, it just crossed our flagging thresholds — early and thin history, so watch whether the next few days confirm the move or fade it.

What’s changed

What the reporting says

Across 27 tracked stories from 12 outlets, reporting on Genentech most often describes launches or releases (3), regulatory approvals (2), military action (1).

It shows up alongside Astrazeneca (8), Bristol Myers Squibb (8), Competing Interest Statement (8), KRAS (8), Abstract (8).

Two steps out: AI (through Abstract, 8 shared stories on the weaker link); Braf (through KRAS, 8 shared stories on the weaker link); Catalyzex Code Finder (through Abstract, 8 shared stories on the weaker link); China (through Astrazeneca, 8 shared stories on the weaker link).

Tracked since May 16, with coverage on 16 separate days — concentrated in Preprint and Kras Research.

Ask the engine about Genentech + Track Genentech for a daily read
Counts computed from our committed signal record (Aug 29 – Aug 29, 1 tracked days). Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Aug 29, 10:29 AM PT